Beactica Therapeutics

Beactica Therapeutics is a specialist drug discovery and development company focusing on combating cancer. Established in 2006 and headquartered in Sweden, the company leverages a molecular interaction-based drug discovery engine to advance a proprietary pipeline of first-in-class therapeutics. This includes a range of small molecule modalities, such as allosteric modulators, protein–protein interaction inhibitors, and targeted protein degraders (PROTACs). Notably, the company received a Venture Round investment on 04 June 2019 from Almi Invest, Unionen, and M2 Capital Management, fueling its mission towards Targeting Genetically Defined Cancers. Beactica Therapeutics operates within the Health Care industry, portraying a strategic focus on novel cancer therapeutics that has attracted notable backing from venture capitalists.